November 16, 2017 08:48 AM EST

X4 raises $27M to take Sanofi’s old drug through pivotal trial

Brittany Meiling

Cambridge, MA-based startup X4 Pharmaceuticals just bagged $27 million to take its two lead drugs — one for cancer, the other for rare disease — to Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

X4 raises $27M to take Sanofi’s old drug through pivotal trial

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Jazz wins approval for bispecific in biliary tract cancer

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Are programs with compounded GLP-1s safe for your population?

X4 rais­es $27M to take Sanofi’s old drug through piv­otal tri­al

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

X4 raises $27M to take Sanofi’s old drug through pivotal trial

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Jazz wins approval for bispecific in biliary tract cancer

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Are programs with compounded GLP-1s safe for your population?